baber/WOPTO huggingface dataset:
Patent NZ-543320-A (NZ)
Title: System and method of facilitating the design of bodyart
Inventor: MADDOCK STEPHEN
Filed: 2006-03-31
Abstract: A system for facilitating the design of body art includes a) data memory in which is stored a style library having a plurality of tattoo design styles and b) at least one processor. Each style is associated with at least one body part and each body part for each tattoo design style associated with at least one tattoo image file. The at least one processor is arranged to perform i) displaying a user interface to the style library on a display. The interface has a body template and at least one library viewer. The body template has a representation of at least one view of an anatomical form that has a combination of body parts at least some of which are below neck level. The at least one processor is further arranged to perform ii) displaying on the library viewer at least one image file for at least one tattoo design style from the style library that is associated with at least one body part that corresponds to at least one body part included in the body template; iii) receiving input from a user selecting at least one body part associated with at least one tattoo design style; and iv) refreshing the body template representation to display the image file for the selected at least one body part and at least one tattoo design style on the corresponding body part of the body template.
Patent NZ-545265-A (NZ)
Title: Pyridazine derivatives and their use for treating diseases mediated by stearoyl-CoA desaturase (SCD) enzymes
Inventor: ABREO MELWYN
IPC: A61K31/501
Filed: 2004-07-29
Abstract: Disclosed are pyridazine derivative compounds of formula (I): wherein x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are as defined in the specification. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. These pyridazine derivatives are suitable for treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) enzymes such as Type II diabetes, impaired glucose tolerance, insulin resistance, obesity, fatty liver, non-alcoholic steatohepatitis, dyslipidemia and metabolic syndrome and any combination of these diseases or conditions.
Patent NZ-550659-A (NZ)
Title: Locks
Inventor: MCKENZIE MALCOLM ROBERT
IPC: E05B63/08
Filed: 2005-04-29
Abstract: A door lock actuable by a handle at each side of the door has a lock handing system for rendering selectively operative/inoperative a rotary actuator (4) associated with each handle so that the lock can be operated only from one side of the door as selected. The handing system is formed by screws (26) selectively insertable and removable from outside of the casing prior to installation to lock or permit rotation of the corresponding actuator when a lock member has been moved to a locking position, such as by key actuation.
Patent NZ-562235-A (NZ)
Title: Benzimidazole and pyridoimidazole derivatives as CRF receptor antagonists, for treating affective disorder, depression, or anxiety
Inventor: ASO KAZUYOSHI
IPC: C07D235/04
Filed: 2006-04-26
Abstract: Disclosed is a compound of formula (I), or a salt thereof, wherein X is -NR3-, Y1 is CR3a, Y2 is CH or C-halogen, Y3 is N or CH, Z is O or -NH-, and wherein the other substituents are as defined in the specification. Also disclosed is a prodrug of the compound wherein the compound has been acylated, alkylated, phosphorylated, or converted into borate or wherein a carboxyl group has been esterified or amidated. Also disclosed is a process for preparing the compound. Also disclosed is the use of the compound as a CRF receptor antagonist, and for treating affective disorder, depression, or anxiety.
Patent NZ-569209-A (NZ)
Title: Substituted imidazoles and their use as pesticides
Inventor: CHUBB NATHAN ANTHONY LOGAN
IPC: A01N43/50
Filed: 2007-01-08
Abstract: Disclosed is an imidazole compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt thereof. Also disclosed is the use of a compound of formula (I) for the manufacture of a medicament for the treatment of a parasitic infection or infestation of insects or acarids.
Patent NZ-571127-A (NZ)
Title: Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
Inventor: SHROFF GEETA
IPC: C12N5/0735
Filed: 2007-03-06
Abstract: Disclosed is a pharmaceutical composition for the treatment of diseases, disorders, or conditions comprising a therapeutic effective amount of human embryonic stem (hES) cells and/or their derivatives, wherein said hES cells and/or their derivatives are free from animal products, feeder cells, growth factors other than beta hCG and progesterone, leukemia inhibiting factor, fibroblast growth factor, vitamin supplements, membrane associated steel factor or soluble steel factor or conditioned media, wherein said hES cells and/or their derivatives are suspended in a pharmaceutically acceptable biocompatible solution and methods for making said composition. Also disclosed are methods of storing hES cells and the use in medicaments.
Patent NZ-572556-A (NZ)
Title: Isothiazolinone biocides enhanced by zinc ions
Inventor: THOMPSON NICHOLAS EDWARD
IPC: A61K33/30
Filed: 2007-05-25
Abstract: An antimicrobial composition comprising (a) at least one isothiazolin-3-one selected from the group consisting of 1,2-benzisothiazolin-3-one, N-(n-butyl)-1,2-benzisothiazolin-3-one, and combinations thereof, and (b) at least one zinc compound selected from the group consisting of zinc salts, zinc oxides, zinc hydroxides, and combinations thereof, wherein said isothiazolin-3-one is present in an amount of from 1 to 500 ppm, the zinc compound is present in an amount of from 5 to 200,000 ppm, and the weight ratio of the isothiazolin-3-one to the zinc compound is from 1:2000 to 100:1.
Patent NZ-575336-A (NZ)
Title: Bicyclic triazoles as protein kinase modulators
Inventor: BOUNAUD PIERRE-YVES
IPC: A61K31/53
Filed: 2007-10-18
Abstract: Disclosed are bicyclic triazole compounds such as 3-[1-(1-ethyl-azetidin-3-yl)-1H-pyrazol-4-yl]-6-(6-methyl-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl)-quinoline. The disclosed bicyclic triazole compounds are used to treat cancer.
Patent NZ-578082-A (NZ)
Title: Testing a building using a first main wire with sensors able to connect to the wire at different sites
Inventor: HOLYOAKE IAN CONRAD
IPC: G01N27/04
Filed: 2009-07-01
Abstract: Disclosed are means for detecting water or moisture in a building, or a quality of a building material within the building. The means include an electrical first line (1) extending to measurement sites within the building; moisture sensors (10-16) connected to the line at different sites; electrical sensor lines (2-8) connected to each sensor; and a resistance meter (9) which can be connected to the line and to any of the sensor lines. The resistance meter enables a selection of any of the sensor lines to create a circuit with the first line. This is such that the meter indicates the resistance at the selected sensor and therefore indicates the moisture or other quality to be tested.
Patent NZ-578980-A (NZ)
Title: Methods for detecting inflammatory bowel disease
Inventor: DIEHL LAURI
IPC: C12Q1/68
Filed: 2008-02-22
Abstract: Provided is a method of detecting inflammatory bowel disease (IBD) in a mammal, comprising detecting the level of expression of a nucleic acid or a gene encoding a LY6 polypeptide (a) in a test sample of tissue or cells obtained from said mammal, and (b) in a control sample, wherein a higher level of expression of the LY6 nucleic acid or polypeptide in the test sample, as compared to the control sample, is indicative of the presence of TED in the mammal from which the test sample was obtained.
Patent NZ-580697-A (NZ)
Title: Catheter comprising a valve and multiple openings, channels and ports that is characterised by one way fluid flow passage
Inventor: GLICKMAN SCOTT
IPC: A61M25/00
Filed: 2008-04-10
Abstract: A catheter (200) for insertion into a hollow viscus of a patient is disclosed. The catheter (200) comprises a drainage opening (204) and an instillation opening (212) at a distal end and an inlet port (209) for instilling a pharmaceutical fluid and an outlet port (205) for draining fluid from viscus at the proximal end. The drainage opening (204) is connected to the outlet port (205) by a drainage channel (201). Similarly, the inlet port (209) is connected to the instillation opening (212) by an instillation channel (211). There is a valve (223) located proximate the drainage opening (204) for closing it against the entry of fluid from viscus. The catheter (200) further comprises a valve control port (220) at the proximal end of the catheter (200) for receiving viscous control gel under pressure. The valve control port (220) is connected to the valve (223) by a control channel (222). In use, the control gel is admitted under pressure through the valve control port (220) and the valve (223) responses by closing itself. The flow of the control gel to the valve (223) through the control channel (222) is one way only and the valve (223) stays closed after the gel has entered the catheter (200) under pressure. This means that the catheter (200) is only designed only for single application.
Patent NZ-583686-A (NZ)
Title: Combinations comprising a fungicidal bacillus strain and an carboxamide
Inventor: SCHOFL ULRICH
IPC: A01N63/00
Filed: 2008-09-16
Abstract: Disclosed is a fungicidal composition for controlling phytopathogenic harmful fungi, comprising 1) a fungicidal strain (I) selected from a) the Bacillus substilis strain with NRRL Accession No. B-21661, and b) the Bacillus pumilus strain with NRRL Accession No. B-30087, or a mutant of these strains having all the identifying characteristics of the respective strain, or a metabolite produced by the respective strain that exhibits activity against plant pathogenic fungi, and 2) at least one chemical compound (II), selected from a carboxamide as defined within the specification.
Patent NZ-584672-A (NZ)
Title: Anti-malarial pharmaceutical composition
Inventor: BOOLES CLIVE
IPC: A61K9/00
Filed: 2008-10-27
Abstract: A pharmaceutical composition for treating a disease such as malaria which is responsive to artemether or arteether is disclosed, wherein the composition comprises: artemether or arteether; and a pharmaceutically-acceptable excipient selected from the group consisting of: medium chain length triglycerides; short chain triglycerides; omega-3-marine triglycerides; and fish oil, rich in omega-3-acids said composition formulated for transmucosal sublingual, buccal or nasal dosage.
Patent NZ-585748-A (NZ)
Title: Amidoalkylamine-comprising azole compositions for protecting industrial materials
Inventor: KOOP BERND
IPC: C07D263/00
Filed: 2010-05-27
Abstract: Disclosed is a use of compositions comprising: at least one azole and at least one amidoalkylamine of the formula (I), a salt and/or acid addition compound thereof, in which R1 represents C1C40-alkyl or C2-C40-alkenyl, R2, R3 and R4 independently of one another represent hydrogen or C1-C8-alkyl and n represents an integer from 1 to 6 for protecting industrial materials (such as wood, timber products or wood/plastic composites) against attack and/or destruction by microorganisms. The disclosure also relates to a composition comprising (a1) at least one azole selected from the group consisting of azaconazole, bitertanol, bromuconazole, cyproconazole, diclobutrazol, difenoconazole, diniconazole, epoxyconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, furconazole, hexaconazole, imibenconazole, ipconazole, myclobutanil, metconazole, penconazole, propiconazole, prothioconazole, simeconazole, tebuconazole, tetraconazole, triticonazole and uniconazole and their metal salts and acid adducts; (a2) optionally one azole selected from the group consisting of triadimenol and triadimefon; and (b) at least one amidoalkylamine of the formula (I).
Patent NZ-594751-A (NZ)
Title: Method of diagnosis of infection by mycobacteria and reagents therefor
Inventor: LINDNER ROBYN
IPC: C12Q1/68
Filed: 2010-02-26
Abstract: 594751 Provided is a method of specifically detecting the presence of one or more Mycobacteria of the M. tuberculosis complex, said method comprising detecting ilvC nucleic acid of one or more Mycobacteria of the M. tuberculosis complex in a sample under conditions that do not detect ilvC nucleic acid of the M. avium complex. Specific primer regions for amplification are also provided.
Patent NZ-596838-A (NZ)
Title: 5-phenyl-[1,2,4 ]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors
Inventor: SMITS KOEN KURT
IPC: A61P19/02
Filed: 2010-06-25
Abstract: Disclosed is cyclopropanecarboxylic acid { 5-[4-(1,1-dioxo-1-thiomorpholin-4-ylmethyl)-phenyl]-[1,2,4]triazolo[1,5-a]pyridine-2-yl} -amide that is useful for treatments of prophylaxis of inflammatory conditions, autoimmune diseases, proliferative diseases and other diseases or disorders associated with hypersecretion of IL-6.
Patent NZ-600150-A (NZ)
Title: Head-end system for advanced metering infrastructure network
Inventor: SFAELOS JIMMY
IPC: G01F15/06
Filed: 2012-05-22
Abstract: 600150 Disclosed is a head-end system (34) for an advanced metering infrastructure (AMI) network. The system (32) includes a processor (40) and a memory accessible by the processor (40). The processor (40) is configured for receiving event signals from AMI meters (30). The event signals are indicative of events occurring at customer locations. The processor (40) determines whether to transmit a command signal to a corresponding AMI meter in response to receiving an event signal from the corresponding AMI meter (30). The command signal is configured to instruct the corresponding AMI meter (30) to perform at least one task in response to the at least one event. The processor (40) transmits the command signal to the corresponding AMI meter in response to determining to transmit the command signal.
Patent NZ-603431-A (NZ)
Title: Parapoxvirus vectors containing rabies virus antigen
Inventor: MARTINON OLIVIER MICHEL
IPC: A61K39/00
Filed: 2011-04-27
Abstract: Disclosed is a recombinant parapoxvirus comprising a parapoxvirus and heterologous DNA derived from a rabies virus.
Patent NZ-619037-A (NZ)
Title: Low-loading titanate inorganic pigments for use in infrared reflective colors
Inventor: WHITE JAMES
IPC: C09D5/33
Filed: 2012-07-03
Abstract: Disclosed herein are titanium dioxide (TiO2) based pigments with low dopant levels (i.e., less than about 5 %) which exhibit coloristic and enhanced infrared (IR) reflectance characteristics that make them useful in formulating colours exhibiting high IR reflectivity, wherein the dopants are selected from the group of metal oxides consisting of manganese oxide (Mn3O4), tungsten oxide (WO3), antimony oxide (Sb2O3), chromium oxide (Cr2O3), and niobium oxide (Nb2O5). Paint compositions comprising the pigments and methods for providing a surface with visual colour and high IR reflectance comprising the step of coating surfaces with said paint compositions are disclosed. Also disclosed are compositions of plastic, concrete, ceramic or glass enamel incorporating an effective amount of the pigment.
Patent NZ-621467-A (NZ)
Title: Vent arrangement for respiratory mask
Inventor: FOOTE ROGER MERVYN LLOYD
IPC: A61M16/01
Filed: 2012-09-13
Abstract: An apparatus for automated control of gas washout of a patient interface of a respiratory treatment apparatus comprising: a vent assembly having a variable size exhaust area defined by one or more overlapping apertures (90, 95), wherein in use the vent assembly vents expiratory gas from the patient interface; and an actuator to manipulate said one or more overlapping apertures of the vent assembly. The variable size exhaust area is configured to be set to a plurality of open positions, the plurality of open positions providing different opening area sizes for venting expiratory gas from the patient interface.
Patent NZ-624471-A (NZ)
Title: Modified rnai agents
Inventor: RAJEEV KALLANTHOTTATHIL G
IPC: C12N15/113
Filed: 2012-11-16
Abstract: Disclosed is a double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene. The dsRNA duplex comprises one or more motifs of three identical modifications on three consecutive nucleotides in one or both strand, particularly at or near the cleavage site of the strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents and the use of such dsRNA agents in the manufacture of a medicament for delivering a polynucleotide to a specific target in a subject.
Patent NZ-627181-A (NZ)
Title: Method of treating atrial fibrillation
Inventor: ZENG DEWAN
IPC: A61P9/06
Filed: 2010-12-20
Abstract: Disclosed herein is a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. Also disclosed are pharmaceutical formulations that are suitable for such combined administration.
Patent NZ-627991-A (NZ)
Title: Liquid formulations of hypoglycaemic sulphonamides
Inventor: BERDUGO POLAK MARIANNE
IPC: A61P27/02
Filed: 2013-02-28
Abstract: Provided are liquid pharmaceutical formulations comprising a hypoglycaemic sulphonamide, at least one thickener, a buffer system maintaining the pH between 4 and 8, and a preservative. The formulations are intended for oral or ophthalmic administration. A preferred hypoglycaemic sulphonamide is glibenclamide. In a preferred embodiment the thickener is a cellulose derivative and a polysaccharide, the buffer system contains lactic acid and sodium citrate, and the preservative is selected from benzoic acid and its sodium or potassium salts.
Patent NZ-629800-A (NZ)
Title: (1r,4r)-6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro-[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for treating fibromyalgia and chronic fatigue syndrome
Inventor: FROSCH STEFANIE
IPC: A61P21/02
Filed: 2013-02-01
Abstract: Disclosed is a pharmaceutical dosage form of compounds of formula (I) for use in the treatment of fibromyalgia or chronic fatigue syndrome. In a particular embodiment, the compound of formula (I) is (1r,4r)-6’-Fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4’,9’-dihydro-3’H-spiro-[cyclohexane-1,1’-pyrano[3,4,b]-indol]-4-amine or a physiologically acceptable salt thereof.
Patent NZ-631047-A (NZ)
Title: Texture analysis of a coated surface using kepler’s planetary motion laws
Inventor: NORRIS ALISON M
IPC: G06F17/18
Filed: 2014-09-11
Abstract: A digital processor is used to receive reflectance data from a target coating, calculate “virtual colour response data” using at least one equation corresponding to at least one of “Kepler’s laws of planetary motion” and at least one equation corresponding to a derivation of at least one of Kepler’s laws of planetary motion , where the virtual colour response data is analogous to one or more eccentricity values, semi-latus rectum values, angular velocity values, mean motion values, areal velocity values , orbital period values, and major axis values. The calculated virtual colour response data is compared to corresponding virtual colour response data stored with an empirical dataset so that the processor can generate a coating formulation that is the same as or substantially similar in appearance to the target coating.
Patent NZ-705049-A (NZ)
Title: Respirable cationic dry powders for delivery to the respiratory tract
Inventor: LIPP MICHAEL M
IPC: A61P11/10
Filed: 2011-09-29
Abstract: Disclosed is a respirable / inhalable dry powder comprising respirable dry particles that comprise a) magnesium lactate; wherein the magnesium lactate provides divalent metal cation in an amount between 0.1% and 2.9% by weight of the dry particle, and b) a pharmaceutical agent such as albuterol, ciprofloxacin, levofloxacin, tobramycin or tiotropium bromide; wherein the respirable dry particles have a volume median geometric diameter (VMGD) of 5 microns or less; and wherein the composition is preferably for the treatment of a respiratory diseases such as asthma, airway hyperresponsiveness, seasonal allergy, bronchiectasis, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, or cystic fibrosis.
Patent NZ-705835-A (NZ)
Title: Textile thigh protector
Inventor: ABRAMOFF RENA
IPC: A41D13/05
Filed: 2013-08-28
Abstract: A garment to for preventing inflammations of the skin between the thighs comprises first portions of the elastic tubular member which have a first thickness. Second portions of the elastic tubular member have a second thickness greater than the first thickness. The first and second portions of the elastic member have an elastic characteristic in a circumferential direction. The first and second portions of the elastic member are interspersed along the surface of the garment to promote the exposure of the thighs underneath the garment to air. A first gripping member or members is disposed along the inner circumference of the tubular member proximate the top of the tubular member. A second gripping member or members disposed along the inner circumference of the tubular member proximate the bottom of the tubular member.
Patent NZ-731467-A (NZ)
Title: Anti-tim3 antibodies and methods of use
Inventor: GEORGES GUY
IPC: C07K16/28
Filed: 2015-11-05
Abstract: The disclosure provides anti-TIM3 antibodies and methods of using the same. These antibodies may be suitable for the treatment of cancer.
Patent NZ-743499-A (NZ)
Title: Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
Inventor: RABOISSON PIERRE
IPC: C07D309/14
Filed: 2013-08-28
Abstract: Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Patent NZ-756827-A (NZ)
Title: Composition containing lactoferrin and sialic acid, preparation method and use thereof
Inventor: YANYU YANG
IPC: A23L33/19
Filed: 2019-08-29
Abstract: The present invention relates to a composition, a process for its preparation and use, in particular a composition comprising lactoferrin and sialic acid, a process for its preparation and use. It belongs to the technical field of food composition and processing technology. A composition comprising lactoferrin and sialic acid, wherein the composition includes, but is not limited to, lactoferrin and sialic acid, and the ratio of the two components in parts by weight is: (5-50): 1; Preferably, parts by weight are (20-40):1; most preferably 30:1. The product obtained by the method of the invention has the mixing rate increased by nearly 50% under the same mixing time; the wall-hanging rate of the whole powder is reduced by about 80%, the waste is reduced by about 58%; the fluidity of the whole powder is improved by about 65%, the production efficiency increased by about 45%; at the same time, the heat resistance of lactoferrin and sialic acid was improved.
Patent PT-100145-A (PT)
Inventor: ADAMS LAUREL MOORE
IPC: A61K35/74
Filed: 1992-02-20
Abstract: This invention provides a method of treating systemic lupus erythematosus in a mammal in need thereof which comprises administering an effective amount of rapamycin orally, parenterally, intranasally, intrabronchially, or rectally.